BACKGROUND: Matrix metalloproteinase 7 (MMP-7) is involved in invasion, metastasis, growth, and angiogenesis. The aim of this study is to assess the prognostic role of serum MMP-7 in curatively resected colorectal cancer (CRC). MATERIALS AND METHODS: Patients undergoing resection for CRC (n = 175) were recruited from July 2003 to December 2004. MMP-7 was determined using a quantitative solid phase sandwich ELISA. Cox analysis was used to assess the role of MMP-7 in predicting overall survival (OS) and disease-free survival (DFS). RESULTS: The median length of follow-up was 45 months (range 1 to 59). Levels of MMP-7 are predictors of DFS (hazard ratio [HR] 1.119, 95% confidence interval [95% CI] 1.038-1.207) and of OS (HR 1.113, 95% CI 1.025-1.209). Patients with MMP-7 higher than the median (4.3 ng/ml) are more likely to relapse (29.5% vs 18.4%, P = .084); median time to progression in relapsed patients is 8 months if MMP-7 is > or =4.3 ng/ml and 18 months if MMP-7 is <4.3 ng/ml. Node-negative patients with low MMP-7 have a predicted probability of relapse-free survival at 4 years of 88% (95% CI 83-92%); if the MMP-7 is higher than the median value; this probability is 77% (95% CI 73-81%). CONCLUSION: MMP-7 predicts recurrence in curatively resected CRC patients.
BACKGROUND:Matrix metalloproteinase 7 (MMP-7) is involved in invasion, metastasis, growth, and angiogenesis. The aim of this study is to assess the prognostic role of serum MMP-7 in curatively resected colorectal cancer (CRC). MATERIALS AND METHODS:Patients undergoing resection for CRC (n = 175) were recruited from July 2003 to December 2004. MMP-7 was determined using a quantitative solid phase sandwich ELISA. Cox analysis was used to assess the role of MMP-7 in predicting overall survival (OS) and disease-free survival (DFS). RESULTS: The median length of follow-up was 45 months (range 1 to 59). Levels of MMP-7 are predictors of DFS (hazard ratio [HR] 1.119, 95% confidence interval [95% CI] 1.038-1.207) and of OS (HR 1.113, 95% CI 1.025-1.209). Patients with MMP-7 higher than the median (4.3 ng/ml) are more likely to relapse (29.5% vs 18.4%, P = .084); median time to progression in relapsed patients is 8 months if MMP-7 is > or =4.3 ng/ml and 18 months if MMP-7 is <4.3 ng/ml. Node-negative patients with low MMP-7 have a predicted probability of relapse-free survival at 4 years of 88% (95% CI 83-92%); if the MMP-7 is higher than the median value; this probability is 77% (95% CI 73-81%). CONCLUSION:MMP-7 predicts recurrence in curatively resected CRC patients.
Authors: Christina Stene; Andrea Polistena; Alexander Gaber; Björn Nodin; Bianca Ottochian; Diya Adawi; Nicola Avenia; Karin Jirström; Louis Banka Johnson Journal: In Vivo Date: 2018 Jan-Feb Impact factor: 2.155
Authors: Christian Niedworok; Frank vom Dorp; Stephan Tschirdewahn; Herbert Rübben; Henning Reis; Miklos Szucs; Tibor Szarvas Journal: Int Urol Nephrol Date: 2016-01-02 Impact factor: 2.370
Authors: Tibor Szarvas; Tobias Jäger; Markus Becker; Stephan Tschirdewahn; Christian Niedworok; Ilona Kovalszky; Herbert Rübben; Süleyman Ergün; Frank vom Dorp Journal: Pathol Oncol Res Date: 2011-01-21 Impact factor: 3.201
Authors: Xabier Garcia-Albeniz; Carles Pericay; Virginia Alonso-Espinaco; Vicente Alonso; Pilar Escudero; Carlos Fernández-Martos; Rosa Gallego; Pere Gascón; Sergi Castellví-Bel; Joan Maurel Journal: Tumour Biol Date: 2010-11-23
Authors: Jelena Urosevic; Xabier Garcia-Albéniz; Evarist Planet; Sebastián Real; María Virtudes Céspedes; Marc Guiu; Esther Fernandez; Anna Bellmunt; Sylwia Gawrzak; Milica Pavlovic; Ramon Mangues; Ignacio Dolado; Francisco M Barriga; Cristina Nadal; Nancy Kemeny; Eduard Batlle; Angel R Nebreda; Roger R Gomis Journal: Nat Cell Biol Date: 2014-06-01 Impact factor: 28.824
Authors: Fee Klupp; Lena Neumann; Christoph Kahlert; Johannes Diers; Niels Halama; Clemens Franz; Thomas Schmidt; Moritz Koch; Juergen Weitz; Martin Schneider; Alexis Ulrich Journal: BMC Cancer Date: 2016-07-18 Impact factor: 4.430